France (FR)

OBSERVATIONAL STUDY OF OUTCOME IN PATIENTS WITH EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS TREATED WITH IMMUNOSUPPRESSIVE THERAPIES (ESOS STUDY) (2016) Herrick AL, Pan X, Peytrignet S, Hesselstrand R, Mouthon L, Brown E, Czirjak L, et al. Conference contribution INTER SPA: SENSITIVITY AND SPECIFITY OF AUTOANTIBODIES AGAINST CD74 IN EARLY AXIAL SPONDYLOARTHRITIS (2016) Riechers E, Baerlecken NT, Baraliakos X, Bakhsh KAM, Aries PM, Bannert B, Becker K, et al. Conference contribution Apremilast Treatment and Long-Term (156-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Analysis of a Large Database of 3 Phase III, Randomized, Controlled Trials (2016) Gladman DD, Kavanaugh A, Gomez-Reino JJ, Wollenhaupt J, Cutolo M, Schett G, Lespessailles E, et al. Conference contribution APREMILAST, AN ORAL PHOSPHODIESTERASE-4 INHIBITOR, IS ASSOCIATED WITH LONG-TERM (104-WEEK) IMPROVEMENTS IN ENTHESITIS AND DACTYLITIS IN PATIENTS WITH PSORIATIC ARTHRITIS: POOLED RESULTS FROM THREE PHASE III RANDOMIZED CONTROLLED TRIALS (2016) Gladman DD, Kavanaugh A, Adebajo AO, Gomez-Reino JJ, Wollenhaupt J, Cutolo M, Schett G, et al. Conference contribution Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-term (104-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Results from Three Phase III, Randomized, Controlled Trials (2016) Gladman D, Kavanaugh A, Adebajo A, Gomez-Reino J, Wollenhaupt J, Cutolo M, Schett G, et al. Conference contribution On a Boltzmann mean field model for knowledge growth (2016) Burger M, Lorz A, Wolfram MT Journal article Soluble CD83 inhibits skin inflammation to chemical sensitizers (2016) Mihatsch P, Boyd P, Krzyzak L, Lechmann M, Nicolas J, Mahler V, Steinkasserer A, Vocanson M Conference contribution THE EUROPEAN SOCIAL PREFERENCE MEASUREMENT (ESPM) STUDY: CONCEPTUAL CONSIDERATIONS AND IMPLEMENTATION (2016) Schlander M, Telser H, Holm S, Marshall DA, Nord E, Richardson J, Garattini S, et al. Conference contribution Novel nanosystems to combat atherosclerosis: Functional effects on human endothelial and monocytic cells (2016) Cicha I, Matuszak J, Juenet M, Chauvierre C, Texier I, Almer G, Prassl R, et al. Conference contribution TREAT CTC: An innovative therapy approach to eliminate circulating tumor cells (CTCs) (2016) Tzschaschel M, Trapp E, Rack B, Messina C, Mueller V, Fehm T, Janni W, et al. Conference contribution